You are here

Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Serious Fungal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Invasive aspergillosis and other serious fungal infections.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT01073618
Pfizer
Completed
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Similar Trials

Common Cold, Upper Respiratory Tract Infections
NCT01257542
All Genders
6+
Years
Multiple Sites
Intra-Abdominal Infections, Infectious Skin Disease
NCT01789905
All Genders
Pneumococcal Infections
NCT03313050
All Genders
50+
Years
Multiple Sites
Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV
Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV
This is non-interventional study of voriconazole IV formulation in clinical use, which was mandated by the Korean government agency following the approval of Vfend in the Republic of Korea.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients who are indicated for VFEND according to drug package insert.
Serious Fungal Infections
Drug: voriconazole IV
6 mg/kg iv q 12 hours (loading) then maintenance
Other Name: Vfend
A.
Patients who are indicated for VFEND according to drug package insert.
Intervention: Drug: voriconazole IV
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
692
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Invasive aspergillosis and other serious fungal infections.

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01073618
A1501067
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now